Tolebrutinib

• Also known as: SAR442168
• Pharmaceutical Company: Sanofi
• Route and Dose of Administration: Oral (once daily)
• Type: Immunomodulator
• Emerging Treatment for: Relapsing Multiple Sclerosis (RMS); Non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS); Primary Progressive Multiple Sclerosis (PPMS)
• Status: In Phase III clinical trials


How it works
Tolebrutinib selectively inhibits the protein, Bruton’s tyrosine kinase or BTK, to reduce the activation of B cells that contribute to brain and spinal cord inflammation in MS. Tolebrutinib has also been proposed to modulate a specific immune cell called microglia, an immune cell of the central nervous system linked to MS progression.  


Relapsing MS Trials
Phase III Trial: GEMINI 1 and GEMINI 2  

Progressive MS Trials
Phase III Trial: HERCULES

Phase III Trial: PERSEUS